December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

20.25 -1.26 (-5.86%)
Streaming Delayed Price Updated: 1:50 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioAge Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
From BioAge Labs, Inc.
Via GlobeNewswire
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗
Don't be too quick to jump on this biotech bandwagon. 
Via The Motley Fool
News headline image
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat ↗
BioAge Labs reported a mixed Q3 2025, beating revenue estimates by 94% with a narrower EPS loss. The clinical-stage biotech advanced its lead drug, BGE-102, with cash runway through 2029. 
Via Chartmill
News headline image
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development. 
Via The Motley Fool
News headline image
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗
This stock has caught fire after some recent events, but how long will that last? 
Via The Motley Fool
News headline image
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗
The clinical-stage biotech is working on a new type of weight management drug. 
Via The Motley Fool
News headline image
Here are the top movers in Thursday's session. ↗
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.